Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Addiction

Therapeutic area intelligence for Addiction with 16 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
16
Catalysts
0
Companies
2

Companies

Dr. Reddy's Labs →
Pfizer →

Assets

Black →
FDA →
Feasibility →
Mirtazapine →
NIAAA →
Pilot →
Psilocybin →
Tirzepatide →
University →
varenicline →

Recent signals(16)

Clinical
August 3, 2026

Pilot Study on Environmental Effects on Alcohol Use Disorder Behavior

A pilot study is evaluating the impact of various activities and environments on drinking behaviors in individuals with alcohol use disorder.

RegulatoryJuly 27, 2026

FDA Accepts Supplement for Buprenorphine and Naloxone from Dr. Reddy's Labs

The FDA has accepted a supplemental application for buprenorphine hydrochloride and naloxone hydrochloride submitted by Dr. Reddy's Labs.

ClinicalJuly 20, 2026

University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses

The Opioid Rapid Response System (ORRS) project aims to train citizens in naloxone administration to reduce opioid overdose deaths.

ClinicalJuly 18, 2026

Study on Oral Nicotine Pouches' Impact on Craving and Brain Response

A study is underway to assess the effects of a 6 mg oral nicotine pouch on craving and brain responses to smoking cues.

ClinicalJuly 9, 2026

Study on rTMS for Methamphetamine Abuse in Methadone Patients Launched

A clinical trial is underway to evaluate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) for treating methamphetamine abuse in patients undergoing methadone maintenance therapy.

ClinicalJuly 5, 2026

Yale University develops culturally adapted CM for Black adults with stimulant use disorder

Yale University is leading a study to create a culturally adapted contingency management protocol targeting Black adults with stimulant use disorder.

ClinicalJuly 5, 2026

Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression

Preliminary results indicate that psilocybin-assisted psychotherapy significantly reduces drinking days and craving frequency in individuals with AUD and depressive symptoms.

RegulatoryJuly 4, 2026

FDA Approval Update for Buprenorphine and Naloxone from Dr. Reddy's Labs

The FDA has accepted the supplemental application ANDA205806 for Buprenorphine Hydrochloride and Naloxone Hydrochloride from Dr. Reddy's Labs.

ClinicalJuly 4, 2026

Pilot Study on Opioid Use Disorder Treatment for Patients with Serious Injection Related Infections

A pilot study is assessing an adapted intervention for Opioid Use Disorder treatment in patients hospitalized with serious injection related infections.

ClinicalJuly 4, 2026

Mirtazapine Shows Promise for Treating Methamphetamine Use in Opioid Disorder Patients

A clinical trial is evaluating Mirtazapine's efficacy in reducing methamphetamine use among opioid use disorder patients receiving medication-assisted treatment.

ClinicalJune 30, 2026

Study on App-Based Incentives for Older Adults with Substance Use Disorders

A study is assessing the effectiveness of app-based incentives for older adults with substance use disorders, comparing their engagement and efficacy to younger adults.

ClinicalJune 28, 2026

Gut Proteobacteria Influence Cocaine Addiction via Glycine Metabolism in Mice

Cocaine exposure alters gut microbiome composition, increasing Proteobacteria and depleting glycine, which affects neuroplasticity and cocaine self-administration in mice.

ClinicalJune 28, 2026

Tirzepatide Evaluated for Cannabis Use Disorder in Proof-of-Concept Study

A proof-of-concept study is underway to evaluate Tirzepatide for treating Cannabis Use Disorder (CUD).

ClinicalJune 26, 2026

NIAAA Launches Study on Addictions Neuroclinical Assessment for Alcohol Use Disorder

The NIAAA is testing a new assessment tool called the Addictions Neuroclinical Assessment (ANA) to better understand alcohol use disorder.

ClinicalJune 24, 2026

Feasibility Study on Olfactory Stimuli in VR for Alcohol Dependence Patients

A feasibility study is evaluating the integration of olfactory stimuli into virtual reality cue exposure for alcohol dependence.

ClinicalJune 18, 2026

Pilot Study on Text-Based Contingency Management for Smoking Cessation Engagement

A pilot study is assessing the feasibility of a text-based contingency management intervention to enhance engagement in smoking cessation treatment.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Alcohol Use Disorder →
Opioid Use Disorder →
Stimulant Use Disorder →
Substance Use Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.